← Other lipid agents × glycemic control

TrialMetabolic syndrome and related disorders2015

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

Harold E Bays et al.PubMed ↗Publisher ↗

What the trial testedas reported · 849 people · 2015

No range given

Reported lower glycemic control, no range given

−40.0percentage points

As reported

difference −40.0 %, no interval

One number in the abstract

the abstract, start to end

… IPE significantly lowered hsCRP levels 40.0% (P=0.0007) in MARINE and 23.0% …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−40.0
Other lipid agentsGlycemic control

Other lipid agents × glycemic controlhelps?mixed

unlikelylikely
0.400.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

8 papers cite it

2015
2016
2017
2018
2019
2020
2021
this papercites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 25893544